Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ Immunomodulators
- 2 April 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (8) , 5137-5156
Abstract
The approvals of idelalisib and duvelisib have validated PI3Kδ inhibitors for the treatment for hematological malignancies driven by the PI3K/AKT pathway. Our program led to the identification of structurally distinct heterocycloalkyl purine inhibitors with excellent isoform and kinome selectivity; however, they had high projected human doses. Improved ligand contacts gave potency enhancements, while replacement of metabolic liabilities led to extended half-lives in preclinical species, affording PI3Kδ inhibitors with low once-daily predicted human doses. Treatment of C57BL/6-Foxp3-GDL reporter mice with 30 and 100 mg/kg/day of 3c (MSD-496486311) led to a 70% reduction in Foxp3-expressing regulatory T cells as observed through bioluminescence imaging with luciferin, consistent with the role of PI3K/AKT signaling in Treg cell proliferation. As a model for allergic rhinitis and asthma, treatment of ovalbumin-challenged Brown Norway rats with 0.3 to 30 mg/kg/day of 3c gave a dose-dependent reduction in pulmonary bronchoalveolar lavage inflammation eosinophil cell count.Keywords
This publication has 44 references indexed in Scilit:
- Targeting phosphoinositide 3‐kinase δ for the treatment of respiratory diseasesAnnals of the New York Academy of Sciences, 2013
- CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling studyHaematologica, 2011
- Discovery of Dual Inhibitors of the Immune Cell PI3Ks p110δ and p110γ: a Prototype for New Anti-inflammatory DrugsChemistry & Biology, 2010
- To scale or not to scale: the principles of dose extrapolationBritish Journal of Pharmacology, 2009
- How regulatory T cells workNature Reviews Immunology, 2008
- Signalling through Class I PI3Ks in mammalian cellsBiochemical Society Transactions, 2006
- Phosphoinositides in cell regulation and membrane dynamicsNature, 2006
- A NOVEL MODEL FOR PREDICTION OF HUMAN DRUG CLEARANCE BY ALLOMETRIC SCALINGDrug Metabolism and Disposition, 2005
- CD69 and Regulatiof the Immune FunctionImmunopharmacology and Immunotoxicology, 1999
- Pharmacological analysis of the activity of the adenosine uptake inhibitor, dipyridamole, on the sinoatrial and atrioventricular nodes of the guinea‐pigBritish Journal of Pharmacology, 1998